HUE067356T2 - IRAK4 inhibitor és BCL-2 inhibitor kombinációban, rák kezelésére való felhasználásra - Google Patents

IRAK4 inhibitor és BCL-2 inhibitor kombinációban, rák kezelésére való felhasználásra

Info

Publication number
HUE067356T2
HUE067356T2 HUE18873778A HUE18873778A HUE067356T2 HU E067356 T2 HUE067356 T2 HU E067356T2 HU E18873778 A HUE18873778 A HU E18873778A HU E18873778 A HUE18873778 A HU E18873778A HU E067356 T2 HUE067356 T2 HU E067356T2
Authority
HU
Hungary
Prior art keywords
inhibitor
bcl
combination
treating cancer
irak4
Prior art date
Application number
HUE18873778A
Other languages
English (en)
Hungarian (hu)
Inventor
Robert Booher
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of HUE067356T2 publication Critical patent/HUE067356T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HUE18873778A 2017-10-31 2018-10-30 IRAK4 inhibitor és BCL-2 inhibitor kombinációban, rák kezelésére való felhasználásra HUE067356T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762579502P 2017-10-31 2017-10-31

Publications (1)

Publication Number Publication Date
HUE067356T2 true HUE067356T2 (hu) 2024-10-28

Family

ID=66328095

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18873778A HUE067356T2 (hu) 2017-10-31 2018-10-30 IRAK4 inhibitor és BCL-2 inhibitor kombinációban, rák kezelésére való felhasználásra

Country Status (27)

Country Link
US (3) US10758518B2 (enExample)
EP (2) EP4410377A3 (enExample)
JP (3) JP7241747B2 (enExample)
KR (2) KR102697663B1 (enExample)
CN (2) CN111225911B (enExample)
AU (3) AU2018359248B2 (enExample)
BR (1) BR112020008214A2 (enExample)
CA (1) CA3079628A1 (enExample)
DK (1) DK3704108T3 (enExample)
EA (1) EA202090497A1 (enExample)
ES (1) ES2979273T3 (enExample)
FI (1) FI3704108T3 (enExample)
HR (1) HRP20240700T1 (enExample)
HU (1) HUE067356T2 (enExample)
IL (3) IL308364B2 (enExample)
LT (1) LT3704108T (enExample)
MX (2) MX2020003666A (enExample)
MY (1) MY203827A (enExample)
NZ (1) NZ762393A (enExample)
PH (1) PH12020550457A1 (enExample)
PL (1) PL3704108T3 (enExample)
PT (1) PT3704108T (enExample)
RS (1) RS65572B1 (enExample)
SG (1) SG11202002386WA (enExample)
SI (1) SI3704108T1 (enExample)
SM (1) SMT202400216T1 (enExample)
WO (1) WO2019089580A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732095B2 (en) 2014-01-13 2017-08-15 Aurigene Discovery Technologies Limited Bicyclic heterocyclyl derivatives as IRAK4 inhibitors
CN110691589A (zh) 2017-03-31 2020-01-14 奥列基因发现技术有限公司 用于治疗血液病的化合物和组合物
FI3704108T3 (fi) * 2017-10-31 2024-05-23 Curis Inc Irak4-estäjä yhdistelmässä bcl-2-estäjän kanssa käytettäväksi syövän hoitoon
TWI832010B (zh) * 2019-09-24 2024-02-11 大陸商上海美悦生物科技發展有限公司 Irak抑制劑及其製備方法和用途
CN115698021A (zh) 2020-04-07 2023-02-03 拜耳公司 经取代的噻唑并吡啶、其盐及其作为除草活性物质的用途
EP4188368A4 (en) * 2020-08-03 2024-09-04 Curis, Inc. Compositions and methods for treating diseases and disorders
MX2023005591A (es) * 2020-11-18 2023-05-29 Curis Inc Metodos de tratamiento de enfermedades y trastornos.
CN116745294A (zh) * 2020-12-25 2023-09-12 南京明德新药研发有限公司 酰胺噁唑类化合物
IL307465A (en) * 2021-04-08 2023-12-01 Curis Inc Combined therapies for cancer treatment
CN113402499B (zh) 2021-06-21 2022-05-13 上海勋和医药科技有限公司 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途
TW202328151A (zh) 2021-09-07 2023-07-16 德商拜耳廠股份有限公司 經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途
TW202328150A (zh) 2021-09-07 2023-07-16 德商拜耳廠股份有限公司 經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途
CN118530221A (zh) * 2021-12-23 2024-08-23 杭州多域生物技术有限公司 一种五元并六元化合物、制备方法、药物组合物和应用
WO2025090844A1 (en) * 2023-10-27 2025-05-01 Curis, Inc. Methods of treating cancer associated with reduced interleukin 1 beta expression

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
DE59010701D1 (de) 1990-05-18 1997-05-22 Hoechst Ag Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
DE69818675T2 (de) 1997-07-29 2004-07-29 Alcon Laboratories, Inc., Fort Worth Galaktomannanpolymere und borat enthaltende augenarzneimittel
JP2002501892A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（−）−ビュープロピオンの薬学的使用
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
DE10023486C1 (de) 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
ATE522525T1 (de) 2003-05-01 2011-09-15 Bristol Myers Squibb Co Arylsubstituierte pyrazolamidverbindungen, die als kinase-inhibitoren von nutzen sind
ATE556067T1 (de) 2003-05-20 2012-05-15 Ajinomoto Kk Modulatoren des vanilloid rezeptors
WO2004108133A2 (en) 2003-06-05 2004-12-16 Vertex Pharmaceuticals Incorporated Modulators of vr1 receptor
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2005034870A2 (en) 2003-10-07 2005-04-21 Renovis, Inc. Amide compounds and ion channel ligands and uses thereof
US20090005249A1 (en) 2004-04-22 2009-01-01 Bayer Cropscience Lp Method and composition for controlling weeds
EP1655297A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1819341A4 (en) 2004-11-10 2011-06-29 Synta Pharmaceuticals Corp IL-12 MODULATORY CONNECTIONS
CA2589678A1 (en) 2004-12-17 2006-06-22 Eli Lilly And Company Novel mch receptor antagonists
CA2589695A1 (en) 2004-12-17 2006-06-22 Eli Lilly And Company Thiazolopyridinone derivates as mch receptor antagonists
EP1674467A1 (en) 2004-12-22 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
US7820821B2 (en) 2006-02-10 2010-10-26 Transtech Pharma, Inc. Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
GB0606429D0 (en) 2006-03-30 2006-05-10 Novartis Ag Organic compounds
US8008481B2 (en) 2006-03-31 2011-08-30 Ericsson Anna M Indazole compounds
WO2007121154A2 (en) 2006-04-11 2007-10-25 Janssen Pharmaceutica, N.V. Substituted benzothiazole kinase inhibitors
JP2010502716A (ja) 2006-09-07 2010-01-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド インターロイキン１受容体関連キナーゼの調節物質
NZ575410A (en) 2006-09-07 2012-03-30 Biogen Idec Inc 2-(1H-Indazol-3-ylamino)-1H-benzimidazole derivatives
WO2008061109A2 (en) 2006-11-15 2008-05-22 Forest Laboratories Holdings Limited Indazole derivatives useful as melanin concentrating receptor ligands
CN101679297B (zh) 2006-12-08 2012-01-11 埃克塞利希斯股份有限公司 Lxr和fxr调节剂
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
WO2009012312A1 (en) 2007-07-16 2009-01-22 Abbott Laboratories Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases
BRPI0814975A2 (pt) 2007-08-08 2015-02-03 Merck Serono Sa Derivados de 6-amino-pirimidina-4-carboxamida e compostos relacionados que se ligam ao receptor de 1-fosfato de esfingosina (s1p) para o tratamento de esclerose múltipla
JP5496915B2 (ja) 2008-02-13 2014-05-21 シージーアイ ファーマシューティカルズ，インコーポレーテッド ６−アリール−イミダゾ［１，２−ａ］ピラジン誘導体、その製造方法、及びその使用方法
US8716312B2 (en) 2008-11-19 2014-05-06 Merck Sharp & Dohme Corporation Inhibitors of diacylglycerol acyltransferase
US8283360B2 (en) 2008-12-19 2012-10-09 Merck Sharp & Dohme Corp. Bicyclic heterocyclic derivatives and methods of use thereof
WO2010072599A1 (en) 2008-12-23 2010-07-01 F. Hoffmann-La Roche Ag Dihydropyridone ureas as p2x7 modulators
CN102656141B (zh) 2009-10-13 2016-04-06 利亘制药公司 模拟造血生长因子的小分子化合物及其用途
JP2013525370A (ja) 2010-04-22 2013-06-20 ヤンセン ファーマシューティカ エヌ．ベー． ケトヘキソキナーゼ阻害剤として有用なインダゾール化合物
AU2011245299A1 (en) 2010-04-30 2012-08-30 Merck Sharp & Dohme Corp. Inhibitors of phosphoinositide dependent kinase 1 (PDK1)
ES2632975T3 (es) 2010-06-24 2017-09-18 Chemocentryx, Inc. Antagonistas de C5aR
CA2802641C (en) 2010-07-13 2019-03-12 Nidhi Arora Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators
MX366318B (es) 2010-11-19 2019-07-05 Ligand Pharm Inc Derivados de aminas heterocíclicas que inhiben la transducción de señal mediana por cinasa asociada con el receptor de interleucina-1.
WO2012084704A1 (en) 2010-12-20 2012-06-28 Merck Serono S.A. Indazolyl triazole derivatives as irak inhibitors
CN103608017B (zh) 2011-04-12 2017-02-15 美国卫生和人力服务部 用于治疗或预防疟疾的疟原虫表面阴离子通道抑制剂
WO2013042137A1 (en) 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
KR20140077963A (ko) 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
GB201119401D0 (en) 2011-11-10 2011-12-21 Ucb Pharma Sa Therapeutic agents
KR101385603B1 (ko) 2012-05-17 2014-04-21 한국원자력의학원 벤조티아졸 유도체 및 암 치료를 위한 그의 용도
WO2014003483A1 (en) 2012-06-29 2014-01-03 Hanmi Pharm. Co., Ltd. Fused pyrimidine derivatives having inhibitory activity on fms kinases
EP2872144A4 (en) 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
WO2014070979A1 (en) 2012-11-03 2014-05-08 Boehringer Ingelheim International Gmbh Inhibitors of cytomegalovirus
US9168257B2 (en) 2013-05-22 2015-10-27 Children's Hospital Medical Center Combination therapy for MDS
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
HK1231480A1 (zh) 2014-01-10 2017-12-22 Aurigene Discovery Technologies Limited 作为irak4抑制剂的吲唑化合物
US9732095B2 (en) * 2014-01-13 2017-08-15 Aurigene Discovery Technologies Limited Bicyclic heterocyclyl derivatives as IRAK4 inhibitors
WO2015119998A1 (en) 2014-02-06 2015-08-13 Abbvie, Inc. 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof
CA2952188A1 (en) * 2014-06-20 2015-12-23 Aurigene Discovery Technologies Limited Substituted indazole compounds as irak4 inhibitors
EP3322698A4 (en) 2015-07-15 2019-01-09 Aurigene Discovery Technologies Limited INDAZOL AND AZAINDAZONE COMPOUNDS AS IRAQ-4 INHIBITORS
AU2016293446A1 (en) 2015-07-15 2018-02-15 Aurigene Discovery Technologies Limited Substituted aza compounds as IRAK-4 inhibitors
JP6994454B2 (ja) * 2015-08-04 2022-01-14 ライジェル ファーマシューティカルズ， インコーポレイテッド ベンズアゾール化合物ならびに該化合物の作製方法および使用方法
US20210292843A1 (en) 2016-10-28 2021-09-23 Children's Hospital Medical Center Treatment of diseases associated with activated irak
FI3704108T3 (fi) * 2017-10-31 2024-05-23 Curis Inc Irak4-estäjä yhdistelmässä bcl-2-estäjän kanssa käytettäväksi syövän hoitoon

Also Published As

Publication number Publication date
PL3704108T3 (pl) 2024-07-22
EP3704108A4 (en) 2021-08-25
JP2023071915A (ja) 2023-05-23
HRP20240700T1 (hr) 2024-08-16
NZ762393A (en) 2025-07-25
US10758518B2 (en) 2020-09-01
SI3704108T1 (sl) 2024-07-31
CN111225911B (zh) 2023-09-01
AU2023222890A1 (en) 2023-09-14
IL315025A (en) 2024-10-01
JP7241747B2 (ja) 2023-03-17
LT3704108T (lt) 2024-06-25
AU2023222890B2 (en) 2025-04-17
US20200345704A1 (en) 2020-11-05
EP4410377A3 (en) 2024-11-13
PT3704108T (pt) 2024-06-11
CA3079628A1 (en) 2019-05-09
IL274248B1 (en) 2024-02-01
SMT202400216T1 (it) 2024-07-09
KR102697663B1 (ko) 2024-08-21
WO2019089580A1 (en) 2019-05-09
CN111225911A (zh) 2020-06-02
KR20200080254A (ko) 2020-07-06
EA202090497A1 (ru) 2020-11-23
CN117064897A (zh) 2023-11-17
RS65572B1 (sr) 2024-06-28
BR112020008214A2 (pt) 2020-10-27
SG11202002386WA (en) 2020-04-29
MX2023010882A (es) 2023-09-27
MY203827A (en) 2024-07-19
AU2018359248B2 (en) 2023-06-01
DK3704108T3 (da) 2024-06-10
IL308364A (en) 2024-01-01
EP4410377A2 (en) 2024-08-07
AU2025205341A1 (en) 2025-07-31
IL274248B2 (en) 2024-06-01
IL308364B2 (en) 2025-02-01
FI3704108T3 (fi) 2024-05-23
AU2018359248A1 (en) 2020-03-26
PH12020550457A1 (en) 2021-03-22
US20190134010A1 (en) 2019-05-09
EP3704108B1 (en) 2024-04-24
IL308364B1 (en) 2024-10-01
IL274248A (en) 2020-06-30
JP2024096919A (ja) 2024-07-17
EP3704108A1 (en) 2020-09-09
MX2020003666A (es) 2020-08-03
KR20240130818A (ko) 2024-08-29
JP7476380B2 (ja) 2024-04-30
US20220370422A1 (en) 2022-11-24
JP2021501145A (ja) 2021-01-14
ES2979273T3 (es) 2024-09-25

Similar Documents

Publication Publication Date Title
HUE067356T2 (hu) IRAK4 inhibitor és BCL-2 inhibitor kombinációban, rák kezelésére való felhasználásra
IL282663A (en) BT1718 for use in cancer treatment
IL267158B (en) Amino-triazopyridine compounds and their use in cancer treatment
IL272596A (en) Pridopidine for use in the treatment of ALS
HUE058323T2 (hu) Egy BTK-inhibitor rák kezelésében történõ alkalmazásra
SG10202005298RA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
IL249020A0 (en) 1,3,4-thiadiazole compounds and their use in cancer treatment
IL271019A (en) Tinostemustine for the treatment of ovarian cysts
IL277629A (en) RET inhibitor for use in the treatment of cancer involving a change in RET
ZA201804361B (en) 1,3,4-thiadiazole compounds and their use in treating cancer
IL259510A (en) 1, 3, 4-thiadiazole compounds and their use for cancer treatment
ZA202007955B (en) Ccr5 inhibitor for use in treating cancer
IL258644A (en) 4,3,1-thiadiazole compounds and their use for cancer treatment
IL261648A (en) Cinnolin-4-amine compounds and their use in treating cancer
LT3406258T (lt) Vaistas, skirtas podagros gydymui
GB201611365D0 (en) A composition for use in treating rotavirus infection
ES3046669T3 (en) Neospora for use in treating cancer
HUE057064T2 (hu) RAD1901 petefészekrák kezelésében történõ alkalmazásra
GB2578008B (en) 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment
PT3813832T (pt) Compostos para utilização na prevenção ou tratamento de cancro
GB201702652D0 (en) Delta-theraphotoxin-Ac1 for use in treating diabetes